Sweden's Spago Nanomedical Q4 net sales plunge, loss narrows

Spago Nanomedical AB (publ)

05/02/2026 07:07

Overview

Swedish clinical developer's Q4 net sales fell sharply yr/yr, while net loss narrowed

Company recommended dose escalation in Tumorad-01 study after positive observations

Company raised MSEK 24.4 in rights issue to fund Tumorad development

Outlook

Company plans dose escalation in Tumorad-01 study to establish maximum tolerated dose

Spago Nanomedical aims for orphan drug designation for Tumorad in adenoid cystic carcinoma

Company raised SEK 25 mln in rights issue to fund Tumorad development

Result Drivers

DOSE ESCALATION - DMC recommended dose escalation in Tumorad-01 study after observing tumor uptake, seen as proof-of-concept

RIGHTS ISSUE - Co raised MSEK 24.4 in rights issue to fund Tumorad development, including dose escalation and Phase IIa preparations

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 4,000
Q4 Adjusted EPS
-SEK 0.01
Q4 Net Income
-SEK 5.89 mln
Q4 Operating Expenses
-SEK 6.94 mln


Analyst Coverage

Wall Street's median 12-month price target for Spago Nanomedical AB (publ) is SEK0.36, about 200.8% above its February 4 closing price of SEK0.12

Press Release: ID:nMFN1MDQ2P

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)